Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig® (erenumab-aooe) In Adult Patients With Episodic Migraine
- Saturday, October 3, 2020, 7:10
- PR Newswire
- Add a comment
THOUSAND OAKS, Calif., Oct. 3, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium….
About the Author
admin has written 20720 stories on this site.